Der Körper verfügt über verschiedene Enzyme, welche die mRNA vor der Translation verändern können. Die Gruppe dieser Enzyme wird als APOBEC zusammengefasst. Das mRNA-Editieren spielt eine wichtige Rolle im Fettstoffwechsel, bei der Infektabwehr (insbesondere viraler Infektionen) und möglicherweise auch in der Tumorgenese. Folglich könnten Störungen in diesen Systemen bei Mutationen der APOBEC-Gene auftreten.
1. |
Zhang J et al. (2004) Rapid evolution of primate antiviral enzyme APOBEC3G. |
2. |
OhAinle M et al. (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. |
3. |
Rogozin IB et al. (2005) APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. |
4. |
Okeoma CM et al. (2010) APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. |
5. |
Santoni de Sio FR et al. (2009) APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. |
6. |
Kamata M et al. (2009) Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. |
7. |
Kinoshita SM et al. (2008) NF-IL6 (C/EBPbeta) induces HIV-1 replication by inhibiting cytidine deaminase APOBEC3G. |
8. |
Chen KM et al. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. |
9. |
Wang T et al. (2007) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. |
10. |
Okeoma CM et al. (2007) APOBEC3 inhibits mouse mammary tumour virus replication in vivo. |
11. |
Chiu YL et al. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. |
12. |
Esnault C et al. (2005) APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. |
13. |
Rösler C et al. (2004) Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". |
14. |
Xu H et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. |
15. |
Turelli P et al. (2004) Inhibition of hepatitis B virus replication by APOBEC3G. |
16. |
Bogerd HP et al. (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. |
17. |
Schröfelbauer B et al. (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). |
18. |
Yu X et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. |
19. |
Marin M et al. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. |
20. |
Sheehy AM et al. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. |
21. |
Harris RS et al. (2003) DNA deamination mediates innate immunity to retroviral infection. |
22. |
Mangeat B et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. |
23. |
Zhang H et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. |
24. |
Vartanian JP et al. (2008) Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. |
25. |
OMIM.ORG article Omim 600130 |